A Phase 3 interventional study of Esomeprazole and Placebo in Prevention, sponsored by AstraZeneca. Completed at 46 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-11-22.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing esomeprazole in Stomach Ulcer — none open to participants now, none under way, none of them phase 3. Esomeprazole · Stomach Ulcer.
Among the 11 studies testing esomeprazole in Stomach Ulcer, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 9 in phase 3, and was the 11th registered.
116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
Browse Stomach Ulcer studies →None of the 11 studies testing esomeprazole in Stomach Ulcer is open now. The open studies under Stomach Ulcer, anywhere →
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 427 is above the median of 298 across 88 interventional studies indexed under Stomach Ulcer.
Median enrollment 400 across the 11 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 2 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
17 studies in Stomach Ulcer by AstraZeneca: none open now, none under way, none of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 17 studies in Stomach Ulcer by AstraZeneca, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2010, is one of 11 in phase 3, and was the 10th registered.
AstraZeneca’s Stomach Ulcer studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing esomeprazole in Stomach Ulcer, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 17 in Stomach Ulcer:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the efficacy of D961H 20 mg once daily (q.d.) versus placebo in continuous treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily Low-dose aspirin therapy by evaluating time from randomisation to occurrence of gastric and/or duodenal ulcers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Esomeprazole 20mg once daily oral
Drug: Esomeprazole
Placebo once daily oral
Drug: Placebo
20mg, capsule, 72 weeks
Placebo, capsule, 72 weeks
Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis.
Assessments for occurrence of gastric and/or duodenal ulcers were performed every 12 weeks after randomisation. The numbers of participants with recurrence of gastric and/or duodeal ulcers were analysed every 12 weeks up to 48 weeks.
Time frame: From randomisation to up to 48 weeks (Maximum follow-up period at the interim analysis)
Change in Degree of Gastric Mucosal Lesion by Modified Lanza Scale From Baseline to Last Measurement up to Week 48
Modified Lanza scale attributes the degree of gastric mucosal lesion, graded on a 5 point scale (0=No hemorrhage, no erosion, 1=One hemorrhage or one erosions, 2=2-10 hemorrhages or erosions, 3=11-25 hemorrhages or erosions, 4=More than 25 hemorrhages or erosions, or ulcer). Higher scores indicate greater severity of gastric mucosal lesion.
Time frame: Up to 48 weeks (Baseline to last measurement)
Number of Participants With Reflux Esophagitis Evaluated by the LA Classification up to Week 48.
Endoscopy was conducted at 12, 24, 36 and 48 weeks after randomisation. At the endoscopy, participants was evaluated whether they have reflux esophagitis or not.
Time frame: 12, 24, 36 and 48 weeks
Change in the Severity of Epigastric Pain From Baseline to Last Measurement up to Week 48
The severity of epigastric pain at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".
Time frame: Up to 48 weeks (Baseline to last measurement)
Change in the Severity of Heartburn From Baseline to Last Measurement up to Week 48.
The severity of heartburn at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".
Time frame: Up to 48 weeks (Baseline to last measurement)
Change in the Severity of Anorexia From Baseline to Last Measurement up to Week 48
The severity of anorexia at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".
Time frame: Up to 48 weeks (Baseline to last measurement)
Change in the Severity of Abdomen Enlarged Feeling From Baseline to Last Measurement up to Week
The severity of abdomen enlarged feeling at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".
Time frame: Up to 48 weeks (Baseline to last measurement)
Change in the Severity of Nausea and/or Vomiting From Baseline to Last Measurement up to Week 48
The severity of Nausea and/or Vomiting at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".
Time frame: Up to 48 weeks (Baseline to last measurement)
Change in the Severity of Discomfort in the Stomach From Baseline to Last Measurement up to Week 48
The severity of Discomfort in the stomach at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".
Time frame: Up to 48 weeks (Baseline to last measurement)
Number of Participants With Adverse Events
Participants who had at least adverse events (AE) which occurred after receiving study drug were counted.
Time frame: Up to 70 weeks at the longest
First participant enrolled on 4 February 2010. On 20 May 2011, the efficacy analysis was completed based on positive results of an interim analysis so that the efficacy data in this report are at the interim analysis. To evaluate the safety, the study was continued. The last participant completed the study on 9 November 2011.
| Milestone | Esomeprazole 20mg | Placebo |
|---|---|---|
| Started | 213 | 214 |
| Completed | 164 | 137 |
| Not completed | 49 | 77 |
| Withdrew: Adverse event | 17 | 22 |
| Withdrew: Withdrawal by subject | 15 | 12 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Study-specific withdrawal criteria | 7 | 33 |
| Withdrew: Eligibility criteria not fulfilled | 4 | 3 |
| Withdrew: Use of prohibited concomitant drug | 4 | 2 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Removal | 1 | 0 |
| Milestone | Esomeprazole 20mg | Placebo |
|---|---|---|
| Started | 213 | 214 |
| Completed | 182 | 182 |
| Not completed | 31 | 32 |
Assessments for occurrence of gastric and/or duodenal ulcers were performed every 12 weeks after randomisation. The numbers of participants with recurrence of gastric and/or duodeal ulcers were analysed every 12 weeks up to 48 weeks.
| Participants | Esomeprazole 20mg | Placebo |
|---|---|---|
| 0 - 12 weeks | 1 | 16 |
| 13 - 24 weeks | 1 | 4 |
| 25 - 36 weeks | 0 | 2 |
| 37 - 48 weeks | 0 | 0 |
Modified Lanza scale attributes the degree of gastric mucosal lesion, graded on a 5 point scale (0=No hemorrhage, no erosion, 1=One hemorrhage or one erosions, 2=2-10 hemorrhages or erosions, 3=11-25 hemorrhages or erosions, 4=More than 25 hemorrhages or erosions, or ulcer). Higher scores indicate greater severity of gastric mucosal lesion.
| Scores on a scale | Esomeprazole 20mg | Placebo |
|---|---|---|
| Change in Degree of Gastric Mucosal Lesion by Modified Lanza Scale From Baseline to Last Measurement up to Week 48 | -0.4 ± 0.6 | 1.3 ± 1.6 |
Endoscopy was conducted at 12, 24, 36 and 48 weeks after randomisation. At the endoscopy, participants was evaluated whether they have reflux esophagitis or not.
| Participants | Esomeprazole 20mg | Placebo |
|---|---|---|
| 12 weeks | 0 | 9 |
| 24 weeks | 1 | 6 |
| 36 weeks | 0 | 3 |
| 48 weeks | 0 | 0 |
The severity of epigastric pain at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".
| Participants | Esomeprazole 20mg | Placebo |
|---|---|---|
| Improved | 11 | 16 |
| Unchanged | 153 | 145 |
| Worsened | 4 | 11 |
The severity of heartburn at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".
| Participants | Esomeprazole 20mg | Placebo |
|---|---|---|
| Improved | 7 | 6 |
| Unchanged | 158 | 154 |
| Worsened | 3 | 12 |
The severity of anorexia at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".
| Participants | Esomeprazole 20mg | Placebo |
|---|---|---|
| Improved | 9 | 10 |
| Unchanged | 156 | 153 |
| Worsened | 3 | 9 |
The severity of abdomen enlarged feeling at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".
| Participants | Esomeprazole 20mg | Placebo |
|---|---|---|
| Improved | 18 | 24 |
| Unchanged | 141 | 141 |
| Worsened | 9 | 7 |
The severity of Nausea and/or Vomiting at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".
| Participants | Esomeprazole 20mg | Placebo |
|---|---|---|
| Improved | 8 | 5 |
| Unchanged | 160 | 154 |
| Worsened | 0 | 13 |
The severity of Discomfort in the stomach at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into "Improved". If the value was same, categorised into "Unchanged". If the value was worsened, categorise into "Worsened".
| Participants | Esomeprazole 20mg | Placebo |
|---|---|---|
| Improved | 13 | 15 |
| Unchanged | 150 | 148 |
| Worsened | 5 | 9 |
Participants who had at least adverse events (AE) which occurred after receiving study drug were counted.
| Participants | Esomeprazole 20mg | Placebo |
|---|---|---|
| Adverse event | 155 | 139 |
| Adverse event (Frequency>=5%) | 70 | 53 |
| Death | 0 | 0 |
| Serious adverse event other than death | 17 | 15 |
| Adverse event leading to discontinuation of study | 17 | 22 |
| Drug-related adverse event | 31 | 29 |
| Severe adverse event | 7 | 10 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esomeprazole 20mg | — | 17/214 (7.9%) | 70/214 (32.7%) |
| Placebo | — | 15/213 (7%) | 53/213 (24.9%) |
| Event | Esomeprazole 20mg | Placebo |
|---|---|---|
| Acute Myocardial InfarctionCardiac disorders | 0/214 | 2/213 |
| Brain Stem HaemorrhageNervous system disorders | 2/214 | 0/213 |
| DehydrationMetabolism and nutrition disorders | 0/214 | 1/213 |
| Hip FractureInjury, poisoning and procedural complications | 0/214 | 1/213 |
| Infective Exacerbation Of Chronic Obstructive Airways DiseaseInfections and infestations | 0/214 | 1/213 |
| PneumoniaInfections and infestations | 0/214 | 1/213 |
| GastroenteritisInfections and infestations | 0/214 | 1/213 |
| Gastritis ErosiveGastrointestinal disorders | 0/214 | 1/213 |
| Diverticulum Intestinal HaemorrhagicGastrointestinal disorders | 0/214 | 1/213 |
| Cardiac MyxomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/214 | 1/213 |
| Event | Esomeprazole 20mg | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 43/214 | 30/213 |
| ConstipationGastrointestinal disorders | 12/214 | 11/213 |
| DuodenitisGastrointestinal disorders | 4/214 | 11/213 |
| Gastric PolypsGastrointestinal disorders | 11/214 | 1/213 |
| Age, Customized(Participants) | Esomeprazole 20mg | Placebo | Total |
|---|---|---|---|
| <=64years | 85 | 71 | 156 |
| Between 65 and 74 years | 82 | 89 | 171 |
| >=75 years | 46 | 54 | 100 |
| Sex: Female, Male(Participants) | Esomeprazole 20mg | Placebo | Total |
|---|---|---|---|
| Female | 43 | 46 | 89 |
| Male | 170 | 168 | 338 |
| Region of Enrollment(Participants) | Esomeprazole 20mg | Placebo | Total |
|---|---|---|---|
| Taiwan | 22 | 21 | 43 |
| Japan | 160 | 160 | 320 |
| Korea, Republic of | 31 | 33 | 64 |
| Helicobacter pylori status(Participants) | Esomeprazole 20mg | Placebo | Total |
|---|---|---|---|
| Positive | 93 | 93 | 186 |
| Negative | 117 | 116 | 233 |
The record gives a start of Feb 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole